Skip to main content
. 2021 Dec 20;47(2):32. doi: 10.3892/or.2021.8243

Figure 7.

Figure 7.

mtDNA mutations with varying percentage levels may lead to acquired CDDP resistance in cancer. The identified mtDNA mutations were found to cause the decrease of mitochondrial complex I activity and the elevation of intracellular ROS levels. ROS upregulate the expression of IAPs and phosphorylation of IкB-α and NF-кB, which led to the decreased sensitivity to CDDP. CDDP, cisplatin; mtDNA, mitochondrial DNA; ROS, reactive oxygen species; IAPs, inhibitors of apoptosis proteins.